



TITLE:

# Identification and characterization of a human mitochondrial NAD kinase.

AUTHOR(S):

Ohashi, Kazuto; Kawai, Shigeyuki; Murata, Kousaku

---

CITATION:

Ohashi, Kazuto ...[et al]. Identification and characterization of a human mitochondrial NAD kinase.. Nature communications 2012, 3: 1248.

ISSUE DATE:

2012-12-04

URL:

<http://hdl.handle.net/2433/168512>

RIGHT:

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.



## ARTICLE

Received 16 Mar 2012 | Accepted 6 Nov 2012 | Published 4 Dec 2012

DOI: 10.1038/ncomms2262

OPEN

# Identification and characterization of a human mitochondrial NAD kinase

Kazuto Ohashi<sup>1</sup>, Shigeyuki Kawai<sup>1</sup> & Kousaku Murata<sup>1</sup>

NAD kinase is the sole NADP<sup>+</sup> biosynthetic enzyme. Despite the great significance of NADP<sup>+</sup>, to date no mitochondrial NAD kinase has been identified in human, and the source of human mitochondrial NADP<sup>+</sup> remains elusive. Here we present evidence demonstrating that a human protein of unknown function, C5orf33, is a human mitochondrial NAD kinase; this protein likely represents the missing source of human mitochondrial NADP<sup>+</sup>. The C5orf33 protein exhibits NAD kinase activity, utilizing ATP or inorganic polyphosphate, and is localized in the mitochondria of human HEK293A cells. C5orf33 mRNA is more abundant than human cytosolic NAD kinase mRNA in almost all tissues examined. We further show by database searches that some animals and protists carry C5orf33 homologues as their sole NADP<sup>+</sup> biosynthetic enzyme, whereas plants and fungi possess no C5orf33 homologue. These observations provide insights into eukaryotic NADP<sup>+</sup> biosynthesis, which has pivotal roles in cells and organelles.

<sup>1</sup>Laboratory of Basic and Applied Molecular Biotechnology, Division of Food and Biological Science, Graduate School of Agriculture, Kyoto University, Uji, Kyoto 611-0011, Japan. Correspondence and requests for materials should be addressed to K.M. (email: kmurata@kais.kyoto-u.ac.jp).

**N**AD<sup>+</sup>, NADP<sup>+</sup> and their reduced forms (NADH and NADPH) function as cofactor involved in oxidative–reductive reactions<sup>1,2</sup>. NAD<sup>+</sup> and NADH mainly function in catabolic reactions, whereas NADP<sup>+</sup> and NADPH are involved in anabolic reactions and defence against oxidative stress<sup>3</sup>. NAD<sup>+</sup> and NADP<sup>+</sup> are also known to function as substrates in several reactions<sup>1,2,4–7</sup>. NAD kinase (NADK; EC 2.7.1.23) is the sole NADP<sup>+</sup>-biosynthetic enzyme known to catalyse phosphorylation of NAD<sup>+</sup> to yield NADP<sup>+</sup>, using ATP or inorganic polyphosphate (poly(P)) as the phosphoryl donor<sup>1</sup>, and has a vital role in the cell. Poly(P) is a linear polymer of orthophosphate residues linked by energy-rich phosphoanhydride bonds; it has been found in bacteria, fungi and tissues of higher plants and animals, including humans<sup>8,9</sup>. Some bacterial and archaeal NADKs utilize both poly(P) and ATP as a phosphoryl donor, although all characterized eukaryotic NADKs use ATP, not poly(P)<sup>10</sup>. Moreover, some bacterial and eukaryotic NADKs also catalyse the phosphorylation of NADH by utilizing ATP to yield NADPH (NADH kinase (NADHK; EC 2.7.1.86) reaction)<sup>10</sup>. NADKs that have higher NADHK activity than NADK activity have also been identified, and in some cases classified as NADHK. So far, only mitochondrial Pos5 of the yeast *Saccharomyces cerevisiae* and peroxisomal NADK3 of the plant *Arabidopsis thaliana* have been experimentally defined as NADHK<sup>3,11–13</sup>.

In the case of yeast, in addition to the gene (*POS5*) encoding mitochondrial Pos5, *S. cerevisiae* has other two NADK genes (*UTR1* and *YEF1*) encoding cytosolic Utr1 and Yef1 (refs 3,14,15). The NADK triple mutant (*utr1 yef1 pos5*) is lethal<sup>11,16,17</sup>, emphasizing the significance of intracellular NADP(H) biosynthesis. The phenotypes of the *POS5* mutant (*pos5*), which are probably caused by decreased mitochondrial NADPH, indicate that Pos5 is responsible for mitochondrial NADP(H) synthesis and again emphasizes the importance of mitochondrial NADP(H)<sup>3,11,12,17</sup>. Moreover, in addition to the gene (*NADK3*) encoding peroxisomal NADK3, *NADK1* and *NADK2* have been identified as NADK genes in *A. thaliana*<sup>13,18</sup>. The products of these genes, NADK1 and NADK2, are localized in the cytosol and chloroplast, respectively<sup>19</sup>. In pea leaf, NADP<sup>+</sup> enters the plant mitochondria<sup>20</sup>; thus, the NADP<sup>+</sup> transporter, which is localized in the inner membrane of mitochondria, is responsible for the supply of plant mitochondrial NADP<sup>+</sup>. In phylogenetic tree analysis, the plant NADK3 homologues, including *A. thaliana* NADK3, are distinguishable from NADK homologues, including Pos5 and Utr1 (ref. 21). However, the structural features of NADK3 homologues have not been reported.


In contrast to yeasts and plants, only a single gene encoding NADK has been found in the human genome; the product of this gene, human NADK, is localized to the cytosol<sup>22,23</sup>. No mitochondrial NADK has been found in human. Pollak *et al.*<sup>23</sup> stated that given the vital role of at least two NADK isoforms in yeast, one would certainly expect more than one mammalian NADK isoform; furthermore, any additional NADK isoforms in mammals should have primary structures substantially different from virtually all previously identified enzymes, at least according to the currently available information<sup>1</sup>. An influx of NAD<sup>+</sup> through human and mammal mitochondrial membrane has been reported<sup>24,25</sup>, but the source of human mitochondrial NADP<sup>+</sup> has remained elusive despite its great significance.

In this study, we identified C5orf33, a human protein of unknown function, as an NADK3 homologue, based on homology search using the primary structure of NADK3 of *A. thaliana* as a query. The C5orf33 protein is a novel human mitochondrial NADK that is responsible for the missing source of mitochondrial NADP<sup>+</sup> in human cells.

## Results

**C5orf33 is a candidate human mitochondrial NADK.** *A. thaliana* NADK3 homologues are distinguishable from NADK homologues on the phylogenetic tree<sup>21</sup>, although there has been no report of the features of the primary structure of NADK3. To obtain more information, we performed a BLASTP<sup>26</sup> search using the primary structure of NADK3 as a query against all organisms in KEGG (Kyoto Encyclopedia of Genes and Genomes website, <http://www.genome.jp/kegg/>); 1,127 proteins were detected as NADK3 homologues (*E*-values, *e*-179 to 9.9) with *E*-values less than 10. Human C5orf33 protein was unexpectedly detected as the 134th homologue (*E*-value, 9e-06), whereas human NADK was detected as the 833rd homologue (*E*-value, 0.25). When BLASTP search was conducted using the primary structure of human NADK as a query, human C5orf33 protein was not included in the detected human NADK homologues (total 1,854 proteins; *E*-values ranging from 0.0 to 6.1) as reported previously<sup>1</sup>, although the C5orf33 protein contains an NADK motif (Pfam, PF01513 (ref. 27)) (Fig. 1a). NADK3 was detected as the 1,817th homologue (*E*-value, 0.49) among human NADK homologues.




BLASTP analysis showed that the primary structure of human C5orf33 protein (442 amino-acid residues) is 25% identical (37% similar) to that of NADK3 (317 residues). Moreover, using Mitoprot, we identified a mitochondrial-targeting sequence in the N-terminus of the primary structure of the C5orf33 protein<sup>28</sup> (Fig. 1a). These features of the primary structure suggested that the C5orf33 protein is a novel candidate human mitochondrial NADK.



**Figure 1 | Structure of C5orf33 protein.** (a) Primary structures of the C5orf33 protein and its truncations. Predicted mitochondrial-targeting sequence and NADK motif are in black and grey, respectively. The amino-acid residue numbers are indicated on the structures. Asterisk in parentheses (\*) indicates the start codon found in pMK3270 and pMK3243, but not in the sequence of C5orf33 variant 1. (b) mRNA structures of C5orf33 transcript variants 1 and 2. Grey arrows indicate open reading frames encoding the indicated proteins. The nucleotide (nt) base and amino-acid (aa) residue numbers are shown. The nucleotide sequences indicated by double-headed arrows are identical between variants 1 and 2. The putative start codon (ATG) is denoted by an asterisk (a,b). The nucleotide sequence of C5orf33 variant 2 (62CTTGATTGAAAGGC TCTAGTTAC<sup>85</sup>) corresponds to the N-terminal region of the Δ100C5orf33 protein (101LALKSSY<sup>108</sup>) (a,b).

**In vivo assay of NADK activity using *S. cerevisiae*.** Two complementary DNAs corresponding to mRNAs from the human *C5orf33* gene, transcript variant 1 (accession no. NM\_001085411.1) and transcript variant 2 (accession no. NM\_153013.3), are deposited in the NCBI database. Transcript variant 1 encodes full-length *C5orf33* protein (442 residues) (Fig. 1a,b; Supplementary Fig. S1). Transcript variant 2 encodes the *C5orf33* protein lacking N-terminal 163 amino acids ( $\Delta 163C5orf33$  protein, 279 residues) (Fig. 1a,b). Note that variant 2 also is encompassed by  $\Delta 100C5orf33$  protein (342 residues; Fig. 1a,b). The NADK activity of *C5orf33*,  $\Delta 62C5orf33$ ,

$\Delta 100C5orf33$  and  $\Delta 163C5orf33$  proteins (Fig. 1a) were examined using the *S. cerevisiae* NADK triple mutant *utr1 yef1 pos5*.  $\Delta 62C5orf33$  protein lacks the 62-residue predicted mitochondrial-targeting sequence. As shown in Fig. 2a, MK1598 cells (an NADK triple mutant having YCplac33-*UTR1*) carrying pRS415 alone were inviable on synthetic complete (SC) + 5-fluoroorotic acid (FOA) due to the loss of YCplac33-*UTR1* and the lethality of the resultant *utr1 yef1 pos5* cell<sup>11</sup>. However, MK1598 cells carrying an additional *S. cerevisiae* mitochondrial NADHK gene (*POS5*) on pRS415 (pMK2127) were viable on SC + FOA, although YCplac33-*UTR1* was dropped (Fig. 2a), indicating that the NADHK activity of Pos5 rescued the lethality of the *utr1 yef1 pos5* cells. MK1598 cells carrying the gene encoding either the full-length *C5orf33* protein (pMK3269) or the  $\Delta 62C5orf33$  protein (pMK3270) were viable on SC + FOA medium, but those carrying the  $\Delta 100C5orf33$  gene (pMK3243) or the  $\Delta 163C5orf33$  gene (pMK3244) were not, indicating that the *C5orf33* and  $\Delta 62C5orf33$  proteins exhibit NADK or NADHK activity.



**In vitro NAD(H)K activities of purified *C5orf33*.** To confirm the NADK or NADHK activity of *C5orf33* protein *in vitro*, we expressed recombinant *C5orf33* and  $\Delta 62C5orf33$  proteins in *Escherichia coli* Rosetta-gami(DE3)pLysS as described in Methods, Supplementary Methods and Supplementary Table S1. *C5orf33* was expressed as an insoluble protein, whereas  $\Delta 62C5orf33$  protein was partially soluble: ~28% of  $\Delta 62C5orf33$  protein was soluble and 72% was insoluble (Supplementary Methods). We purified the soluble  $\Delta 62C5orf33$  protein using TALON column chromatography; the resulting product is referred to hereafter as 'purified *C5orf33* protein' (Fig. 2b). SDS-PAGE analysis showed that the molecular mass of the purified *C5orf33* protein was 43 kDa, in agreement with the predicted mass (45 kDa; His-tag (1.4 kDa) plus  $\Delta 62C5orf33$  protein (43.3 kDa)). We assayed the NADK activity of *C5orf33* protein using ATP and poly(P) (metaphosphate) as a phosphoryl donor; by thin layer chromatography (TLC) analysis, we detected the formation of NADP<sup>+</sup> from NAD<sup>+</sup> and of ADP from ATP (Fig. 2c), showing that *C5orf33* protein has NADK activity using ATP and poly(P) as phosphoryl donors.

The kinetic properties of *C5orf33* protein were determined by assay of NADK activity using the continuous method (see Methods), and compared with those of human NADK<sup>29</sup> (Table 1). Both  $K_m$  (for NAD<sup>+</sup>) and  $V_{max}$  of *C5orf33* protein ( $0.022 \pm 0.001$  mM and  $0.091 \pm 0.001$  U mg<sup>-1</sup>) were significantly lower than those of human NADK (1.07 mM and 18.5 U mg<sup>-1</sup>)<sup>29</sup>

**Figure 2 | NADK activity of *C5orf33* protein.** (a) *In vivo* assay of NADK activity of *C5orf33* protein. *S. cerevisiae* MK1598 cells (an NADK triple mutant having YCplac33-*UTR1*) carrying the indicated plasmids were spotted onto the solid media and were incubated at 30 °C for 4 days. *C5orf33* protein was less effective than  $\Delta 62C5orf33$  protein in reverting the lethality. We speculate that this is because in the yeast, human *C5orf33* is less able to supply cytosolic NADP<sup>+</sup> than the yeast mitochondrial Pos5 itself. (b) SDS-PAGE of purified *C5orf33* protein (arrowhead; 43 kDa). (c) NADK activity of purified *C5orf33* protein analysed by TLC in the presence (+) or absence (-) of indicated compounds as described in the Methods. (d) Saturation curves for NAD<sup>+</sup> of purified human NADK (dashed line)<sup>29</sup> and *C5orf33* protein (line) determined under 8 and 2 mM ATP, respectively. The specific activity (U μmol<sup>-1</sup>; 1 μmol NADP<sup>+</sup> produced per 1 min and 1 μmol subunit of the enzyme) was calculated using the subunit molecular mass of *C5orf33* protein (45 kDa) or human NADK (43 kDa) (Table 1). Each point represents the average of three determinations; error bars represent s.d.



(Table 1). However, at the physiological concentrations of  $\text{NAD}^+$  found in human mitochondria and cytosol, the NADK activity of C5orf33 protein would be comparable to that of human NADK, as described in the Discussion (Fig. 2d). With regard to the substrate specificity of C5orf33 protein, the NADHK activity of C5orf33 protein was only 10% of its NADK activity (Table 1), although the primary structure of C5orf33 protein is similar to that of NADHK (NADK3 (ref. 13)). ATP-dependent nicotinic acid adenine dinucleotide (NAAD) kinase activity of C5orf33 protein was not detected by TLC. NAAD phosphate (NAADP), the phosphorylated NAAD, is a calcium-mobilizing second messenger in human<sup>6,7</sup>. Although NADKs (Utr1 and Yef1) of *S. cerevisiae* catalyse NAADP synthesis by phosphorylation of NAAD<sup>16</sup>, human NADK has no NAAD phosphorylation activity<sup>22</sup>. Furthermore, TLC analysis detected no phosphorylation of either ADP-ribose, adenosine or 5'-AMP by C5orf33 protein. Sphingosine kinase, diacylglycerol kinase and 6-phosphofructokinase activities of purified C5orf33 protein were assayed by monitoring formation of ADP, as described in Supplementary Methods. Although formation of ADP was observed in the presence of  $\text{NAD}^+$  even in the presence of vehicle alone (16% (v/v) dimethylformamide or 10% (v/v) ethanol), formation of ADP in the presence of sphingosine, diacylglycerol (1,2-dioleoyl-*sn*-glycerol) and fructose 6-phosphate was not, indicating that purified C5orf33 protein exhibits no sphingosine kinase, diacylglycerol kinase or 6-phosphofructokinase activity, although these kinases have been suggested to be weakly related to NADK with respect to structure and function<sup>30</sup>.

On the other hand, as phosphoryl donors, C5orf33 protein could use ATP, other nucleotide triphosphates and poly(P) (metaphosphate, hexametaphosphate and tetrapolyphosphate), but neither ADP, trimetaphosphate, phosphoenolpyruvate nor phosphocreatine (Table 1). It should be noted that C5orf33 protein exhibits a poly(P)-dependent NADK activity comparable to that of its ATP-dependent activity, as it has been postulated

that only a subset of bacterial or archaeal NADKs exhibit high poly(P)-dependent NADK activity, whereas eukaryotic NADKs do not<sup>10</sup>. Moreover, C5orf33 protein exhibited a saturation curve with ATP (Supplementary Fig. S2), whereas human NADK exhibited sigmoidal kinetics with ATP<sup>29</sup>.

Although human NADK is inhibited by NADH and NADPH, but not  $\text{NADP}^+$  (ref. 29), the NADK activity of C5orf33 protein was inhibited by NADH, NADPH and in particular  $\text{NADP}^+$  (Table 1).

**Mitochondrial localization of C5orf33 protein.** C5orf33 protein was predicted to be localized in mitochondria because of the presence of a mitochondrial-targeting sequence (Fig. 1a). An *in vivo* assay of C5orf33 protein localization in *S. cerevisiae* indicated that the C5orf33 protein is localized in mitochondria of *S. cerevisiae*, whereas  $\Delta 62\text{C5orf33}$  protein that lacks the mitochondrial-targeting sequence is not (Supplementary Fig. S3). To confirm the localization of C5orf33 protein in mitochondria of human cells, HEK293A cells were transiently transfected with a plasmid expressing C terminally FLAG-fused C5orf33 protein or  $\Delta 62\text{C5orf33}$  protein, and observed by fluorescence microscopy after immunostaining (Fig. 3). This observation demonstrated that the C5orf33 protein is localized in mitochondria, whereas  $\Delta 62\text{C5orf33}$  protein is not, confirming that C5orf33 protein is a mitochondrial NADK, and that its N-terminal 62 residues contain a functional mitochondrial-targeting sequence. Moreover, we separated the mitochondrial and cytosolic fractions of siRNA-transfected HEK293A cells and confirmed using anti-C5orf33 antibody that C5orf33 protein was localized in the mitochondrial fraction but not in the cytosolic fraction as below (Fig. 5e).

**Widespread expression of C5orf33 mRNA.** To determine whether C5orf33 gene is transcribed in human tissue under physiological conditions, tissue-specific transcription of mRNAs

**Table 1 | Properties of C5orf33 protein and human NADK.**

	C5orf33 protein	Human NADK*
Molecular mass (subunit)	75 kDa (45 kDa)	170 kDa (43 kDa)
Subunit composition	Homodimer†	Homotetramer
$K_m$ (ATP)	$1.7 \pm 0.3$ mM	$3.6$ mM‡
$K_m$ (tetrapolyphosphate)	$1.2 \pm 0.1$ mM	—§
$K_m$ ( $\text{NAD}^+$ )	$0.022 \pm 0.001$ mM	$1.07$ mM
$V_{\max}$	$0.091 \pm 0.001$ U $\text{mg}^{-1}$	$18.5$ U $\text{mg}^{-1}$
Localization	Mitochondria	Cytosol¶
Phosphoryl acceptor#	$\text{NAD}^+$ (100), NADH (10), NAAD (n.d.**), ADP-ribose (n.d.), Adenosine (n.d.), 5'-AMP (n.d.), Sphingosine (n.d.), Diacylglycerol (n.d.), Fructose 6-phosphate (n.d.)	$\text{NAD}^+$ (100), NADH (5.0), NAAD (n.d.)††
Phosphoryl donor‡‡	ATP (100), dATP (99), ADP (n.d.), GTP (162), CTP (56), TTP (87), UTP (41), ITP (104), dITP (141), Metaphosphate (280), Hexametaphosphate (194), Tetrapolyphosphate (84)§§, Trimetaphosphate (n.d.), Tripolyphosphate (n.d.), Phosphoenolpyruvate (n.d.), Phosphocreatine (n.d.)	ATP (100), Metaphosphate (2.3), Hexametaphosphate (1.9), Tetrapolyphosphate (0.5)
Inhibition	None (100), NADH (34), $\text{NADP}^+$ (58), NADPH (17)	None (100), NADH (40), $\text{NADP}^+$ (102), NADPH (81)

\*Almost all of these data were determined previously<sup>29</sup>.

†Subunit composition was regarded as homodimeric, as the molecular mass of purified C5orf33 was estimated to be ~75 kDa.

‡ $S_{0.5}$  is shown, as human NADK exhibits sigmoidal kinetics towards ATP<sup>29</sup>.

§Not determined because the tetrapolyphosphate-dependent NADK activity (0.5%) of human NADK is much lower than the ATP-dependent activity.

|| $V_{\max}$  for  $\text{NAD}^+$ .  $V_{\max}$  for ATP and tetrapolyphosphate were  $0.088 \pm 0.005$  and  $0.095 \pm 0.004$  U  $\text{mg}^{-1}$ , respectively.

¶Demonstrated previously<sup>23</sup>.

#The relative NADK activities determined in the presence of 2 mM phosphoryl acceptors are shown, taking the activity in 2 mM  $\text{NAD}^+$  as 100%.


\*\*Not detected.

††Demonstrated previously<sup>22</sup>.

‡‡The relative NADK activities determined in the presence of 5 mM phosphoryl donors, 2.4  $\text{mg ml}^{-1}$  metaphosphate, or 2.4  $\text{mg ml}^{-1}$  hexametaphosphate are shown, taking the activity in 5 mM ATP as 100%.

§§NADK activity yielded a saturation curve up to 4 mM tetrapolyphosphate; the activity was slightly inhibited in this assay condition (that is, at 5 mM tetrapolyphosphate).


||||The NADK activities of C5orf33 protein and human NADK were assayed in the presence of 1 mM  $\text{NAD}^+$  with or without 0.5 mM NADP<sup>+</sup>, NADH or NADPH. For each protein, activity in the absence of inhibitor was taken as 100%. The inhibitory effect of NADH could not be attributed to the NADHK activity of C5orf33 protein alone, as the NADHK activity assayed in the presence of 0.5 mM NADH was only 13% of the NADK activity assayed in the presence of 1 mM  $\text{NAD}^+$ .



**Figure 3 | Localization of C5orf33 protein in mitochondria of human cells.** HEK293A cells were transiently transfected with plasmid expressing C terminally FLAG-tagged C5orf33 or  $\Delta 62$ C5orf33 protein. The cells were fixed and immunostained with a rabbit anti-FLAG primary antibody and AlexaFluor 488-conjugated anti-rabbit secondary antibody. Mitochondria were stained with MitoTracker Red.

encoding C5orf33 protein, human NADK and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were examined by absolute qPCR. The gene encoding GAPDH was selected as a housekeeping gene<sup>31,32</sup>. For absolute qPCR, standard curves were created using synthesized mRNAs of the genes encoding C5orf33 proteins, human NADK and GAPDH. As shown in Fig. 4, the presence of mRNAs encoding C5orf33 protein, human NADK and GAPDH were confirmed in all examined tissues. The relative levels of transcripts of the GAPDH gene in testes, small intestine, colon, stomach and placenta were in agreement with those reported<sup>32</sup>, guaranteeing the quality of the RNAs at least in these tissues. The mRNA levels of C5orf33 protein and human NADK were only a few per cent of the levels of GAPDH (for example, only 2.1% (human NADK gene) and 7.8% (C5orf33 gene) in brain) (Fig. 4a). However, levels of C5orf33 mRNA were higher than those of the human NADK gene in all tissues examined except for colon, spleen and skeletal muscle (Fig. 4b). In particular, C5orf33 mRNA levels were significantly higher than human NADK mRNA levels in heart, liver, testes and small intestine. The mRNA levels of both genes were low in skeletal muscle, possibly reflecting the virtual absence of both the pentose phosphate and the fatty acid synthetic pathways in this tissue<sup>22</sup>.

**C5orf33 affects mitochondrial reactive oxygen species (ROS) generation.** To obtain information regarding the physiological role of C5orf33 protein, we knocked down the human C5orf33 gene by siRNA transfection of HEK293A cells. Of the six siRNA



**Figure 4 | Tissue-specific mRNA levels determined by absolute qPCR.** mRNAs of C5orf33 protein (dark grey), human NADK (light grey) and GAPDH (white bars) (a); only those of the C5orf33 protein and human NADK are shown in panel b. Means and s.d. of three determinations are shown.

duplexes we tested (Supplementary Table S2), transfection with siRNA#2 resulted in maximum C5orf33 knockdown (~70% reduction) and siRNA#2 was selected for subsequent knockdown experiments (Supplementary Methods and Fig. 5a).

At 2 or 3 days after transfection with siRNA#2, we observed substantial knockdown at the mRNA level (Fig. 5a). At 3 days after transfection with either siRNA#2 or MISSION siRNA Universal Negative Control #1 (control siRNA), C5orf33 mRNA levels were higher than those in the corresponding samples that had been incubated for 1 or 2 days after transfection. We also made observations at the protein level, using anti-C5orf33 antibody. We detected obvious knockdown of C5orf33 protein levels at 2 days and especially 3 days after transfection, but not after a 1-day incubation (Fig. 5b). In accordance with the relative increase in C5orf33 transcript level 3 days after transfection, the absolute level of C5orf33 protein was highest at this time point. The anti-C5orf33 antibody was specific for purified C5orf33 protein, and did not detect purified human NADK, guaranteeing that the signal we detected accurately represented C5orf33 protein rather than a cross-reaction with NADK (Supplementary Fig. S4). By contrast, the anti-human NADK antibody was non-specific, detecting both C5orf33 protein and human NADK (Supplementary Fig. S4).


Next, we evaluated the effect of the C5orf33 knockdown. Mitochondrial morphology was not affected by knockdown of C5orf33 for 3 days after transfection (Supplementary Fig. S5).

During this period, cell viability was also unaffected by knock-down, even in the presence of menadione (Supplementary Fig. S5, Fig. 5c). However, intracellular ROS levels were obviously increased 3 days after knockdown of C5orf33, but not 1 and 2 days, either in the absence or presence of menadione, although ROS levels were higher following menadione treatment (Supplementary Fig. S5, Fig. 5d). Menadione is cytotoxic to various cell lines, including HEK293 (refs 33,34), and induces apoptosis of cultured cells via elevation of peroxide and superoxide radical levels<sup>35</sup>. Moreover, we separated the mitochondrial and cytosolic fractions of HEK293A cells that had been incubated for 3 days after transfections with siRNA#2 and control siRNA, and again confirmed the mitochondrial localization of C5orf33 protein as well as the knockdown of C5orf33 protein level in mitochondrial fraction of siRNA#2-transfected cells, using anti-C5orf33 antibody (Fig. 5e). NADK activity of the mitochondrial fraction was decreased to 47% upon knockdown of C5orf33 (Fig. 5f). These observations indicate that C5orf33 protein, that is, human mitochondrial NADK is involved in the regulation of the generation of mitochondrial ROS.

## Discussion

Only a single gene encoding NADK has been previously reported to exist in the human genome; the product of this gene, human NADK, is localized in cytosol<sup>22,23</sup>. Until now, no mitochondrial NADK had been identified in human. Thus, the source of human mitochondrial NADP(H) has been elusive despite its great significance. In this study, it was revealed that the C5orf33 protein is a novel human mitochondrial NADK that is responsible for the missing source of mitochondrial NADP<sup>+</sup> in human cells. In HEK293 human cells, the concentration of NAD<sup>+</sup> in whole cells and mitochondria are 0.37 and 0.25 mM, respectively<sup>36</sup>. Given that mitochondria occupy 15% of the volume of a neuron<sup>37</sup>, we estimated the cytosolic concentration of NAD<sup>+</sup> to be 0.39 mM. On the other hand, the concentration of ATP, which complexed with magnesium, is estimated to be 2 and 8 mM in mitochondria and cytosol of HeLa cell, respectively<sup>38</sup>. From a saturation curve determined in the presence of 2 mM ATP (the physiological concentration within mitochondria)<sup>38</sup>, we estimated the NADK activity of C5orf33 protein at 0.25 mM NAD<sup>+</sup> to be 3.5 U per 1  $\mu$ mol of C5orf33 protein (Fig. 2d). In the same manner, the activity of human NADK at 0.39 mM NAD<sup>+</sup> was estimated to be 12 U per 1  $\mu$ mol of human NADK subunit in the presence of 8 mM ATP (cytosolic concentration of ATP)<sup>38</sup> (Fig. 2d). Moreover, C5orf33 mRNA levels were higher than those of human NADK in almost all tissues (Fig. 4). Collectively, although the  $V_{max}$  of C5orf33 protein is significantly lower than that of human NADK (Table 1), under physiological conditions the NADK activity of the C5orf33 protein would be comparable to that of human NADK.

BLASTP analyses using each of the primary structures of human C5orf33 protein and human NADK as a query in eukaryotic protein databases detected 107 C5orf33 homologues



**Figure 5 | siRNA transfection.** HEK293A cells were transfected with siRNA#2 against C5orf33 protein (C5orf33 siRNA) or control siRNA, and incubated for 1, 2 and 3 days. **(a)** Levels of C5orf33 mRNA in the transfected cells are shown as relative values normalized against the level in control siRNA-transfected cells incubated for 1 day after transfection. Knockdowns of 69, 63 and 79% relative to the control, as indicated, were obtained. **(b)** Expression of C5orf33 protein in the transfected cells. Proteins were analysed by western blotting using anti-C5orf33 and anti-GAPDH antibodies. **(c)** Viability. Transfected cells incubated for 3 days were treated with 12.5  $\mu$ M menadione (black bar) or vehicle (0.62% (v/v) dimethyl sulfoxide (DMSO), grey bar) for 20 h, and viability was measured using calcein AM as in Supplementary Methods. Viability was also measured using MTT as in Supplementary Fig. S5. **(d)** Intracellular ROS levels. Transfected cells incubated for 3 days were incubated with 10  $\mu$ M 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) for 30 min, and then treated without (grey bar) or with (black bar) 100  $\mu$ M menadione for 30 min; intracellular ROS was measured as described in Supplementary Methods. *t*-test; \**P* = 0.0085, \*\**P* = 0.0026, \*\*\**P* = 0.0022, \*\*\*\**P* = 0.0044  $\times 10^{-4}$ . Viability and intracellular ROS levels are presented as relative values normalized against their respective levels in control siRNA-transfected cells not treated with menadione; each independent experiment was conducted in duplicate (**c,d**). **(e)** Mitochondrial and cytosolic fractions of HEK293A cells that had been incubated for 3 days after transfections. Mitochondrial (M; 1.9  $\mu$ g) and cytosolic (C; 1.9  $\mu$ g) fractions and whole cells (W; from  $3.3 \times 10^4$  transfected HEK293A cells) were analysed by western blotting using anti-CoxII, anti-GAPDH and anti-C5orf33 antibodies. CoxII and GAPDH are mitochondrial and cytosolic markers, respectively<sup>49</sup>. **(f)** NADK activity of mitochondrial fraction obtained in panel e. Mitochondrial NADK activity is expressed as pmol of NADP<sup>+</sup> formed in 1 h. NADK activity was decreased to 47% upon knockdown of C5orf33. *t*-test; \**P* = 0.024. Means and s.d. of three independent determinations are shown (**a,c,d,f**).



and 316 human NADK homologues, all of which contain the NADK motif. Phylogenetic trees constructed based on the structures of the 107 proteins as described in Supplementary Methods gave three clades: (i) animal and protist proteins including the human C5orf33 protein (total 65 proteins;  $E$ -values from 0.0 to 0.074); (ii) plant proteins including NADK3 (18 proteins;  $E$ -values from  $8e-11$  to 0.049); and (iii) other proteins from several eukaryotes (24 proteins;  $E$ -values from 0.017 to 5.4) (Supplementary Fig. S6). These clades were, respectively, designated as (i) C5orf33 homologues, (ii) plant NADK3 homologues and (iii) NADK homologues. The 24 other proteins from several eukaryotes were found in 316 human NADK homologues, gave much lower  $E$ -values ranging from 0.0 to  $4e-51$ , and hence were designated as NADK homologues. Predicted mitochondrial-targeting sequences were detected in the primary structures of 38 of 65 C5orf33 homologues, and 4 of 18 plant NADK3 homologues, but not in 24 NADK homologues (Supplementary Fig. S6). Given that eukaryotes consist of animals (for example, vertebrates and insects), protists, plants and fungi, we concluded that animals and protists, but not plants and fungi, have C5orf33 homologues. C5orf33 homologues were found in almost all animals and many protists; 48 of 52 animals and 13 of 29 protists. Although 42 of 52 animals and 5 of 29 protists possess both C5orf33 and NADK homologues, some carry only either a C5orf33 homologue or NADK homologue; one protist (*Naegleria gruberi*) has none (Supplementary Table S3). It is noteworthy that six animals (for example, pig and horse) and eight protists (for example, those in genus *Plasmodium*) possess the C5orf33 homologue as sole NADP<sup>+</sup> biosynthetic enzyme.

We performed multiple alignment of the primary structures of human C5orf33 protein, plant NADK3 and nine NADKs (Supplementary Fig. S7). The GGDG motif<sup>39</sup>, NE/D short motif<sup>40</sup>, and the Asp, Thr and Tyr residues (corresponding to Asp-189, Thr-200 and Tyr-202 of Ppnk (NADK of *Mycobacterium tuberculosis*) and taking part in the creation of NAD<sup>+</sup>-binding site) in the NADK-conserved region<sup>40,41</sup> are completely conserved in the primary structures of the nine NADKs. In the structure of the C5orf33 protein, although the GGDG motif and NE/D short motif were completely conserved, the Asp, Thr and Tyr residues were not, corresponding instead to Ser-306, Lys-317 and Trp-319. We also found an additional region, termed the C5orf33 additional region, in the structure of the C5orf33 protein. In the sequence of NADK3, the GGDG motif and NE/D short motif are conserved; the Asp, Thr and Tyr residues were Ser-209, Thr-220 and Ala-222; and the NADK3 additional region, which does not correspond to the C5orf33 additional region, is found.

In the aligned structures of 65 C5orf33 homologues, the GGDG motif was conserved in 58 of 65 structures; the NE/D short motif was completely conserved (that is, in 65 of 65 structures) (Supplementary Fig. S7). With regard to the Ser-306, Lys-317 and Trp-319 of the human C5orf33 protein, the Ser-306 was conserved as Ser/Thr, the Trp-319 was completely as Trp, although the Lys-317 was not conserved and corresponded to Lys/Ser/Thr/Arg. In the aligned structures of C5orf33 homologues, we found two conserved sequences, motif 1 and motif 2. Motif 1 is PX-GXN(T/S)DP; motif 2 is S-G-X(C/M), where X and hyphen (-) mean hydrophobic (Ile, Phe, Val, Leu and Met) and any amino-acid residues, respectively. Of the aligned 65 sequences, 50 possessed both motifs; of the remaining 15 sequences, 3 contained motif 1 alone, 8 contained motif 2 alone and 4 contained neither. The sequences corresponding to the C5orf33 additional region were also found in 62 of the 65 aligned sequences.

In the aligned structures of 18 plant NADK3 homologues, the GGDG motif, the NE/D short motif and motif 1 were completely conserved (in 18 of 18 sequences); motif 2 was almost completely

conserved (in 17 of 18 sequences). The Ser-209, Thr-220 and Ala-222 residues of NADK3, corresponding to Asp-189, Thr-200 and Tyr-202 of Ppnk, were conserved as Ser, Thr/Ser and Ala residues. Sequences corresponding to the NADK3 additional region were found in 17 of the 18 sequences (Supplementary Fig. S7). Taken together, these structural features may contribute to the unique properties of human C5orf33 protein, that is, high capacity to utilize poly(P), as well as low  $K_m$  and low  $V_{max}$ , and inhibition by NADP<sup>+</sup> and of plant NADK3, that is, low  $K_m$  and high  $V_{max}$  for NADH<sup>13</sup>, possibly by using a different set of active-site side chains.

## Methods

**Plasmids.** The plasmids and primers used in this study are listed in Supplementary Tables S4 and S5. Briefly, pMK2127 is pRS415 carrying the *POS5* promoter ( $P_{pos5}$ ) driving *POS5* (ref. 11). Genes encoding C5orf33 (full-length) and its truncations (Fig. 1a) were inserted into downstream  $P_{pos5}$  by replacing *POS5* of pMK2127 with these genes. Genes encoding C5orf33 and its deleted proteins were also inserted into *BamHI/SmaI* site of pQE-80L (Qiagen), yielding pMK3271, pMK3272 and pMK3241, respectively. These proteins were expressed as His (MRGSHHHHHHGS; 1.4 kDa)-tagged proteins to their N-termini. For expression of C terminally FLAG-tagged human C5orf33 and  $\Delta 62$ C5orf33 proteins in HEK293A cells, cDNAs of human C5orf33 and  $\Delta 62$ C5orf33 were inserted into pFLAG-CMV-5a (Sigma), yielding pMK3602 and pMK3603, respectively. For absolute qPCR, DNA sequences corresponding to cDNA of human GAPDH (1,310 bp; 1,008 bp of *GAPDH* gene, 5'-flanking 102 bp and 3'-flanking 200 bp), human NADK (3,032 bp; 1,341 bp of human NADK gene, 5'-42 bp, 3'-1,649 bp), and C5orf33 variant 1 (3,852 bp; 1,324 bp of *C5orf33* gene and 3'-2,528 bp) were inserted into pBluescript II SK (+), yielding pMK3420, pMK3421 and pMK3422, respectively. Accurate synthesis of all the constructed plasmids was confirmed by DNA sequencing.

**Yeast strains and cultivations.** For the cultivation of yeast, standard yeast media (yeast extract/peptone/dextrose, SC and synthetic dextrose media) were used<sup>42</sup>. If required, amino acids were added to synthetic dextrose medium. Liquid medium were solidified using 2% agar. Yeast cells were cultured aerobically at 30 °C. For plasmid shuffling, solid SC medium containing 0.1% FOA (SC + FOA medium) was used. FOA is toxic for the cells containing *URA3* (ref. 43).

*S. cerevisiae* strains in BY4742 background (*MATa leu2 $\Delta$ 0 lys2 $\Delta$ 0 ura3 $\Delta$ 0 his3 $\Delta$ 1*) were used. *S. cerevisiae* MK1598 cell is an NADK triple mutant carrying *YCplac33-UTR1* (BY4742 *utr1 $\Delta$ ::kanMX4 yef1 $\Delta$ ::HIS3 pos5 $\Delta$ ::hphMX4 YCplac33-UTR1*) and is lethal on SC + FOA medium<sup>11,16</sup>.

**In vitro assays.** NADK activity of purified C5orf33 protein was assayed at 37 °C by the modified continuous method as described previously<sup>29</sup>. Briefly, NADPH formation was continuously measured at  $A_{340}$  in a reaction mixture (1 ml) containing 5 mM NAD<sup>+</sup>, 5 mM ATP, 5 mM glucose 6-phosphate, 0.5 U glucose 6-phosphate dehydrogenase (Sigma, St Louis, MD), 5 mM MgCl<sub>2</sub> (40 mM MgCl<sub>2</sub> in the case of the determination of  $K_m$  and  $V_{max}$  for ATP, 20 mM MgCl<sub>2</sub> in that of  $K_m$  and  $V_{max}$  for NAD<sup>+</sup>), 100 mM Tris-HCl (pH 8.0) and appropriate concentration of purified protein. NADK activity was also assayed by a stop method as described previously<sup>29</sup>. When NADK activity was analysed by TLC, 5  $\mu$ l of the reaction mixture containing 5 mM NAD<sup>+</sup>, 5 mM MgCl<sub>2</sub>, 100 mM Tris-HCl (pH 8.0), 4.8  $\mu$ g of purified C5orf33 protein and 5 mM ATP or 2.4 mg ml<sup>-1</sup> metaphosphate was incubated overnight at 37 °C. Metaphosphate was used at 2.4 mg ml<sup>-1</sup>, as 2.4 mg ml<sup>-1</sup> sodium tetrapolyphosphate is 5 mM. Authentic compounds and the incubated reaction mixture were spotted onto a TLC glass plate silica gel 60F254 (Merck), dried, developed with a solvent system of isobutyrate—500 mM NH<sub>4</sub>OH (5:3 v/v)<sup>44</sup> and detected by exposure to UV light at 254 nm. The inhibitory effects of NADP<sup>+</sup>, NADH and NADPH on NADK assay were investigated by a stop method as described previously<sup>29</sup>. The NADHK activity was assayed as described previously<sup>29</sup> in a reaction mixture (1 ml) containing 2 mM NADH, 5 mM ATP, 5 mM MgCl<sub>2</sub>, 100 mM Tris-HCl (pH 8.0) and purified protein. NADK activity of C5orf33 protein was determined by a stop method to compare it with the NADHK activity of the enzyme. NADK activity of mitochondrial fraction was also assayed by the stop method in the reaction mixture as above (40  $\mu$ l; 5 mM NAD<sup>+</sup>, 5 mM ATP, 5 mM MgCl<sub>2</sub>, 100 mM Tris-HCl (pH 8.0) and mitochondrial preparations (1.4–35  $\mu$ g protein)) followed by cycling assay of NADP<sup>+</sup> as described<sup>45</sup>. In each experiment, the assays were linear with respect to both times (0, 1 and 2 h) and concentrations of mitochondrial preparations (at least two points).

One unit of enzyme activity was defined as 1  $\mu$ mol NADP<sup>+</sup> or NADPH produced in 1 min at 37 °C; specific activity was expressed in U mg<sup>-1</sup> protein, unless otherwise stated. Kinetic values were calculated by fitting the data to the appropriate Michaelis–Menten equations using Kaleidagraph software (Synergy Software).



**Expression and purification of C5orf33 protein.** To express C5orf33 and  $\Delta 62C5orf33$  proteins, MK3274 and MK3275 cells (*E. coli* Rosetta-gami(DE3)pLysS (Novagen) cells carrying pMK3271 and pMK3272, respectively) were precultured overnight in 700 ml LB medium (350 ml per 500 ml Sakaguchi flask) supplemented with  $100 \mu\text{g ml}^{-1}$  ampicillin and  $34 \mu\text{g ml}^{-1}$  chloramphenicol. The cells collected from the cultures ( $\sim 75$  or 700 ml culture) were inoculated in 1.5 or 13.5 l LB medium (1.5 per 2 l Sakaguchi flask) supplemented with the same antibiotics, and aerobically cultured at  $37^\circ\text{C}$ , until  $A_{600}$  reached 0.50–1.0. Isopropyl- $\beta$ -D-thiogalactopyranoside was then added to obtain a final concentration of  $25 \mu\text{M}$  and cell cultivation was continued further at  $16^\circ\text{C}$  under aerobic conditions for 5 days. The conditions for expression were determined as described in Supplementary Methods and Supplementary Table S1. The crude extract was prepared as described<sup>29</sup>. The  $\Delta 62C5orf33$  protein was purified as described in Supplementary Methods and the purified protein was regarded as purified C5orf33 protein.

**Transfection and indirect immunofluorescence microscopy.** HEK293A cells cultivated in Dulbecco's modification of Eagle's minimal essential medium containing 10% fetal bovine serum (DMEMs) supplemented with penicillin ( $50 \mu\text{g ml}^{-1}$ ) and streptomycin ( $50 \mu\text{g ml}^{-1}$ ) on coverslips at  $37^\circ\text{C}$  were transfected with pMK3602 or pMK3603 by Lipofectamine 2000 (Invitrogen), and further cultivated for 2 days at  $37^\circ\text{C}$ . The transfected HEK293A cells were stained with MitoTracker Red CMXRos (500 nM in fresh DMEMs; Molecular Probes) for 45 min, washed with PBS, fixed with 3.7% formaldehyde in PBS, permeabilized with 0.2% Triton X-100 in PBS and blocked using PBS containing 3% bovine serum albumin (BSA). The primary antibody was rabbit anti-FLAG (Sigma) and the secondary antibody was AlexaFluor 488-conjugated anti-rabbit IgG (Invitrogen). Images were acquired using an inverted FV1000-D IX81 (Olympus, Tokyo, Japan) microscope.

**Absolute qPCR.** Human total RNAs were purchased from Clontech and Agilent Technologies. The synthesized mRNAs of GAPDH, human NADK, and C5orf33 variant 1 (Supplementary Fig. S1) were prepared using the *in vitro* Transcription T7 kit (Takara, Otsu, Japan) using as templates, respectively, pMK3420, pMK3421, and pMK3422 linearized by *Xho*I. The molar concentration of the synthesized mRNAs was calculated from  $A_{260}$ , and the calculated molecular mass of the synthesized mRNAs (GAPDH, 413 kDa; human NADK, 943 kDa; C5orf33 variant 1, 1,193 kDa). RNA was isolated from siRNA-transfected HEK293A cells using Sepasol-RNA I Super G (Nacalai Tesque, Kyoto, Japan). cDNAs were prepared from RNA and quantitated by absolute qPCR using LineGene (BioFlux, Tokyo, Japan) and SYBR Green Real-time PCR Master Mix (Toyobo) as described in Supplementary Methods.

**siRNA transfection.** The siRNA duplexes (Sigma) for knockdown of C5orf33 gene are listed in Supplementary Table S2. MISSION siRNA Universal Negative Control #1 (control siRNA; Sigma) was used as siRNA duplex for a negative control. Other details were described in Supplementary Methods. Cell viability of the transfected HEK293A cells was measured using 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) or calcein AM (Molecular Probes) and intracellular ROS of the cells were detected as described<sup>23,33,46</sup> and in Supplementary Methods.

**Western blotting.** Proteins were separated by SDS-PAGE<sup>47</sup> and analysed using anti-C5orf33 (Abnova, rabbit polyclonal, 1:2,500 dilution or 1:312,500 as in Supplementary Fig. S4), anti-cytochrome C oxidase subunit II (EPR3314) (CoxII; Abcam, rabbit monoclonal, 1:10,000), anti-GAPDH (6C5) (loading control; Abcam, mouse monoclonal, 1:500), anti-human NADK (Abnova, mouse monoclonal, 1:500 as in Supplementary Fig. S4) antibodies, which were diluted in Can Get Signal solution 1 (Toyobo). Horseradish peroxidase-conjugated anti-rabbit IgG (HRP-anti-rabbit IgG; Amersham Biosciences) and HRP-anti-mouse IgG (Amersham Biosciences) were diluted in Can Get Signal solution 2 (Toyobo) at dilutions of 1:2,000 and 1:10,000, respectively. MagicMark XP Western Standard (Invitrogen) or Precision Plus Protein Standard (Bio-Rad) was used as the standard. For proteins in lysates of transfected HEK293A cells, cells in  $4 \times 0.6$  ml transfection-mixture were collected by treatment with trypsin/EDTA solution (Nacalai Tesque), suspended and boiled for 10 min in  $48 \mu\text{l}$  1 $\times$  SDS buffer. Signal intensities were estimated using ImageQuant TL.

**Preparation of mitochondria.** From transfected HEK293A cells, we prepared mitochondria using the Mitochondria Isolation Kit for Cultured Cells (MitoSciences). Details are described in Supplementary Methods.

**Other analytical methods.** Protein concentration of the crude extract was determined by the Bradford method<sup>48</sup>, and BSA was used for a standard. The concentration of purified C5orf33 protein was determined using  $A_{280}$ . A solution containing purified C5orf33 protein with  $A_{280}$  of 1.0 was calculated to contain  $0.9 \text{ mg ml}^{-1}$  from the molar extinction coefficient (51,255), and the calculated molecular mass (46,353 Da) of the C5orf33 protein using ExPASy (<http://br.expasy.org/tools/protparam.html>). The molecular mass of the enzyme was

estimated by gel filtration chromatography as described previously<sup>29</sup>. The phylogenetic tree was constructed as described in Supplementary Methods.

## References

- Pollak, N., Dolle, C. & Ziegler, M. The power to reduce: pyridine nucleotides—small molecules with a multitude of functions. *Biochem. J.* **402**, 205–218 (2007).
- Ziegler, M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. *Eur. J. Biochem.* **267**, 1550–1564 (2000).
- Outten, C. E. & Culotta, V. C. A novel NADH kinase is the mitochondrial source of NADPH in *Saccharomyces cerevisiae*. *EMBO J.* **22**, 2015–2024 (2003).
- Smith, J. S. *et al.* A phylogenetically conserved NAD<sup>+</sup>-dependent protein deacetylase activity in the Sir2 protein family. *Proc. Natl Acad. Sci. USA* **97**, 6658–6663 (2000).
- Yamasaki, M. *et al.* Organelle selection determines agonist-specific Ca<sup>2+</sup> signals in pancreatic acinar and beta cells. *J. Biol. Chem.* **279**, 7234–7240 (2004).
- Aarhus, R., Graeff, R. M., Dickey, D. M., Walseth, T. F. & Lee, H. C. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. *J. Biol. Chem.* **270**, 30327–30333 (1995).
- Rutter, G. A. Calcium signalling: NAADP comes out of the shadows. *Biochem. J.* **373**, e3–e4 (2003).
- Morimoto, D. *et al.* Inorganic polyphosphate differentiates human mesenchymal stem cells into osteoblastic cells. *J. Bone Miner. Metab.* **28**, 418–423 (2010).
- Kornberg, A., Rao, N. N. & Ault-Riche, D. Inorganic polyphosphate: a molecule of many functions. *Annu. Rev. Biochem.* **68**, 89–125 (1999).
- Kawai, S. & Murata, K. Structure and function of NAD kinase and NADP phosphatase: key enzymes that regulate the intracellular balance of NAD(H) and NADP(H). *Biosci. Biotechnol. Biochem.* **72**, 919–930 (2008).
- Miyagi, H., Kawai, S. & Murata, K. Two sources of mitochondrial NADPH in the yeast *Saccharomyces cerevisiae*. *J. Biol. Chem.* **284**, 7553–7560 (2009).
- Strand, M. K. *et al.* POS5 gene of *Saccharomyces cerevisiae* encodes a mitochondrial NADH kinase required for stability of mitochondrial DNA. *Eukaryot. Cell* **2**, 809–820 (2003).
- Turner, W. L., Waller, J. C. & Snedden, W. A. Identification, molecular cloning and functional characterization of a novel NADH kinase from *Arabidopsis thaliana* (thale cress). *Biochem. J.* **385**, 217–223 (2005).
- Kawai, S., Suzuki, S., Mori, S. & Murata, K. Molecular cloning and identification of UTR1 of a yeast *Saccharomyces cerevisiae* as a gene encoding an NAD kinase. *FEMS Microbiol. Lett.* **200**, 181–184 (2001).
- Shi, F., Kawai, S., Mori, S., Kono, E. & Murata, K. Identification of ATP-NADH kinase isozymes and their contribution to supply of NADP(H) in *Saccharomyces cerevisiae*. *FEBS J.* **272**, 3337–3349 (2005).
- Bieganski, P., Seidle, H. F., Wojcik, M. & Brenner, C. Synthetic lethal and biochemical analyses of NAD and NADH kinases in *Saccharomyces cerevisiae* establish separation of cellular functions. *J. Biol. Chem.* **281**, 22439–22445 (2006).
- Shianna, K. V., Marchuk, D. A. & Strand, M. K. Genomic characterization of POS5, the *Saccharomyces cerevisiae* mitochondrial NADH kinase. *Mitochondrion* **6**, 94–101 (2006).
- Turner, W. L., Waller, J. C., Vanderbeld, B. & Snedden, W. A. Cloning and characterization of two NAD kinases from *Arabidopsis*. Identification of a calmodulin binding isoform. *Plant Physiol.* **135**, 1243–1255 (2004).
- Waller, J. C., Dhanoa, P. K., Schumann, U., Mullen, R. T. & Snedden, W. A. Subcellular and tissue localization of NAD kinases from *Arabidopsis*: compartmentalization of *de novo* NADP biosynthesis. *Planta* **231**, 305–317 (2010).
- Bykova, N. V. & Moller, I. M. Involvement of matrix NADP turnover in the oxidation of NAD-linked substrates by pea leaf mitochondria. *Physiol. Plant.* **111**, 448–456 (2001).
- Ando, T. *et al.* Structural determinants of discrimination of NAD<sup>+</sup> from NADH in yeast mitochondrial NADH kinase Pos5. *J. Biol. Chem.* **286**, 29984–29992 (2011).
- Lerner, F., Niere, M., Ludwig, A. & Ziegler, M. Structural and functional characterization of human NAD kinase. *Biochem. Biophys. Res. Commun.* **288**, 69–74 (2001).
- Pollak, N., Niere, M. & Ziegler, M. NAD kinase levels control the NADPH concentration in human cells. *J. Biol. Chem.* **282**, 33562–33571 (2007).
- Purvis, J. L. & Lowenstein, J. M. The relation between intra- and extramitochondrial pyridine nucleotides. *J. Biol. Chem.* **236**, 2794–2803 (1961).
- Rustin, P. *et al.* Fluxes of nicotinamide adenine dinucleotides through mitochondrial membranes in human cultured cells. *J. Biol. Chem.* **271**, 14785–14790 (1996).
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. *J. Mol. Biol.* **215**, 403–410 (1990).
- Bateman, A. *et al.* The Pfam protein families database. *Nucleic Acids Res.* **30**, 276–280 (2002).

28. Claros, M. G. & Vincens, P. Computational method to predict mitochondrially imported proteins and their targeting sequences. *Eur. J. Biochem.* **241**, 779–786 (1996).
29. Ohashi, K., Kawai, S., Koshimizu, M. & Murata, K. NADPH regulates human NAD kinase, a NADP<sup>+</sup>-biosynthetic enzyme. *Mol. Cell Biochem.* **355**, 57–64 (2011).
30. Labesse, G., Douguet, D., Assairi, L. & Gilles, A. M. Diacylglyceride kinases, sphingosine kinases and NAD kinases: distant relatives of 6-phosphofructokinases. *Trends Biochem. Sci.* **27**, 273–275 (2002).
31. Nishimura, M. & Naito, S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. *Biol. Pharm. Bull.* **28**, 886–892 (2005).
32. Nishimura, M., Naito, S. & Yokoi, T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. *Drug Metab. Pharmacokinet.* **19**, 135–149 (2004).
33. Nishiyama, T. *et al.* Cooperation of NAD(P)H:quinone oxidoreductase 1 and UDP-glucuronosyltransferases reduces menadione cytotoxicity in HEK293 cells. *Biochem. Biophys. Res. Commun.* **394**, 459–463 (2010).
34. Okayasu, H., Ishihara, M., Satoh, K. & Sakagami, H. Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. *Anticancer Res.* **21**, 2387–2392 (2001).
35. Sakagami, H., Satoh, K., Hakeda, Y. & Kumegawa, M. Apoptosis-inducing activity of vitamin C and vitamin K. *Cell. Mol. Biol.* **46**, 129–143 (2000).
36. Yang, H. *et al.* Nutrient-sensitive mitochondrial NAD<sup>+</sup> levels dictate cell survival. *Cell* **130**, 1095–1107 (2007).
37. Honma, S. *et al.* Quantitative ultrastructure of synapses on functionally identified primary afferent neurons in the cat trigeminal mesencephalic nucleus. *Exp. Brain Res.* **137**, 150–162 (2001).
38. Imamura, H. *et al.* Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. *Proc. Natl Acad. Sci. USA* **106**, 15651–15656 (2009).
39. Kawai, S., Mori, S., Mukai, T., Hashimoto, W. & Murata, K. Molecular characterization of *Escherichia coli* NAD kinase. *Eur. J. Biochem.* **268**, 4359–4365 (2001).
40. Mori, S. *et al.* NAD-binding mode and the significance of intersubunit contact revealed by the crystal structure of *Mycobacterium tuberculosis* NAD kinase-NAD complex. *Biochem. Biophys. Res. Commun.* **327**, 500–508 (2005).
41. Raffaelli, N. *et al.* Characterization of *Mycobacterium tuberculosis* NAD kinase: functional analysis of the full-length enzyme by site-directed mutagenesis. *Biochemistry* **43**, 7610–7617 (2004).
42. Sherman, F. Getting started with yeast. *Methods Enzymol.* **350**, 3–41 (2002).
43. Boeke, J. D., Trueheart, J., Natsoulis, G. & Fink, G. R. 5-Fluoroorotic acid as a selective agent in yeast molecular genetics. *Methods Enzymol.* **154**, 164–175 (1987).
44. Murata, K., Uchida, T., Tani, K., Kato, J. & Chibata, I. Metaphosphate: a new phosphoryl donor for NAD phosphorylation. *Agric. Biol. Chem.* **44**, 61–68 (1980).
45. Zerez, C. R., Lee, S. J. & Tanaka, K. R. Spectrophotometric determination of oxidized and reduced pyridine nucleotides in erythrocytes using a single extraction procedure. *Anal. Biochem.* **164**, 367–373 (1987).
46. Chen, Q., Behar, K. L., Xu, T., Fan, C. & Haddad, G. G. Expression of *Drosophila* trehalose-phosphate synthase in HEK-293 cells increases hypoxia tolerance. *J. Biol. Chem.* **278**, 49113–49118 (2003).
47. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680–685 (1970).
48. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**, 248–254 (1976).
49. Vogel, R. O. *et al.* Cytosolic signaling protein Ecsit also localizes to mitochondria where it interacts with chaperone NDUFAF1 and functions in complex I assembly. *Genes Dev.* **21**, 615–624 (2007).

## Acknowledgements

This work was partially supported by the Funding Program for Next Generation World-Leading Researchers (to S.K.) and by Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (to S.K.). We thank Dr Teruo Kawada, Dr Nobuyuki Takahashi and Mr Tomoya Sakamoto, Graduate School of Agriculture, Kyoto University, for providing us with HEK293A cells and for technical assistance with cultivation and immunostaining of these cells.

## Author contributions

K.O. and S.K. designed and performed experiments. K.O., S.K. and K.M. wrote the manuscript. S.K. and K.M. reviewed/edited the manuscript.

## Additional information

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Ohashi, K. *et al.* Identification and characterization of a human mitochondrial NAD kinase. *Nat. Commun.* 3:1248 doi: 10.1038/ncomms2262 (2012).



This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>